Regional variations in the prevalence of multiple sclerosis in French farmers

Vukusic, Sandra; van Bockstael, Vincent; Gosselin, Sophie; Confavreux, Christian
July 2007
Journal of Neurology, Neurosurgery & Psychiatry;Jul2007, Vol. 78 Issue 7, p707
Academic Journal
Background: Studies on the prevalence of multiple sclerosis have been carried out worldwide, showing a heterogeneous distribution between countries and even between the different regions of the same country. Methods: We estimated the regional and national prevalence of multiple sclerosis in France on 1 January 2003, based on the computerised database of the national farmer health insurance system (‘Mutualité Sociale Agricole’). Results: There were 2667 cases of multiple sclerosis registered on the prevalence date, out of 4 098 477 affiliates. After standardisation on age, estimates for the national prevalence of multiple sclerosis in French farmers were 65.0 per 100 000 inhabitants (95% confidence interval 62.5 to 67.5), 41.9 per 100 000 in men (39.1 to 44.7) and 96.3 per 100 000 in women (92.0 to 100.6). The prevalence of multiple sclerosis was significantly higher in the north eastern regions (approximately 100 per 100 000 inhabitants) compared with the south western regions (around 50 per 100 000 inhabitants). Conclusion: Our study is the first to evaluate the overall prevalence of multiple sclerosis in France and its 22 regions using the same methodology. Our results may be generalised to the whole French population as there is no convincing evidence of an increased or decreased susceptibility to multiple sclerosis among farmers or persons living in the countryside. This places France among the countries of medium to high prevalence. Confirming the uneven distribution of multiple sclerosis that correlates with latitude, raises once more the question of the role of genetic and environmental factors in the susceptibility to multiple sclerosis.


Related Articles

  • Access to health care for people with multiple sclerosis. Minden, S. L.; Frankel, D.; Hadden, L.; Hoaglin, D. C. // Multiple Sclerosis (13524585);May2007, Vol. 13 Issue 4, p547 

    The Sonya Slifka Longitudinal Multiple Sclerosis (MS) Study follows a population-based cohort of approximately 2000 people with MS to study demographic and clinical characteristics, use and cost of health services, provider and treatment characteristics, neurological, economic, and psychosocial...

  • Factors that influence adherence with disease-modifying therapy in MS. Treadaway, Katherine; Cutter, Gary; Salter, Amber; Lynch, Sharon; Simsarian, James; Corboy, John; Jeffery, Douglas; Cohen, Bruce; Mankowski, Ken; Guarnaccia, Joseph; Schaeffer, Lawrence; Kanter, Roy; Brandes, David; Kaufman, Charles; Duncan, David; Marder, Ellen; Allen, Arthur; Harney, John; Cooper, Joanna; Woo, Douglas // Journal of Neurology;Apr2009, Vol. 256 Issue 4, p568 

    The complexity and cost of injection treatment can represent a formidable challenge for patients affected by a chronic illness, particularly those whose treatment is primarily preventative and only modestly effective on the more conspicuous symptomatic aspects of the disease process. The aim of...

  • The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics. Minden, S. L.; Frankel, D.; Hadden, L.; Perloff, J.; Srinath, K. P.; Hoaglin, D. C. // Multiple Sclerosis (13524585);Feb2006, Vol. 12 Issue 1, p24 

    The Sonya Slifka Longitudinal Multiple Sclerosis Study follows a population-based cohort of approximately 2000 people with multiple sclerosis (MS) to study demographic and clinical characteristics, course of illness, utilization and cost of health services, provider characteristics, use of MS...

  • Progress in the diagnosis and treatment of multiple sclerosis. HOU Shi-fang; LIU Yin-hong; XU Xian-hao // Chinese Journal of Contemporary Neurology & Neurosurgery;Oct2014, Vol. 14 Issue 10, p849 

    The growing number of disease modifying drugs (DMDs) approved for multiple sclerosis (MS) treatment is a significant step forward and provides new options for MS patients. This article summarizes the clinical research highlights of MS, including clinical manifestations, accessory examinations,...

  • NÄ›které poznatky z kontrolní a revizní činnosti pracoviÅ¡Å¥ centrové péče soustÅ™eďujících léčbu nemocných s diagnózou roztrouÅ¡ená skleróza... Václav, Ranč // Revision & Assessment Medicine / Revizni a Posudkove Lekarstvi;Aug/Nov2012, Vol. 15 Issue 3/4, p116 

    The article exemplifies obstacles of the financial cost control on the case of therapy of multiple sclerosis. Prescription and indication limits are issues by SUKL (State Institute of Drug Control) and in this legal way limits the possibility of justified compensation paid by insurance companies...

  • MS costs could be reduced in Ireland.  // PharmacoEconomics & Outcomes News;Sep2014, Vol. 712 Issue 1, p23 

    The article reports on the statement of researchers from Ireland that multiple sclerosis (MS) is associated with high levels of healthcare resource use and costs that increase with disability and could be reduced by interventions that prevent progression.

  • I EAT PRETTY. Grison, Deborah D. // Washington Informer;3/14/2013, Vol. 48 Issue 22, p27 

    A personal narrative is presented which explores the author's experience of battling with pre-symptomatic multiple sclerosis and improving her health conditions.

  • Cladribine reduces healthcare resource use in MS.  // PharmacoEconomics & Outcomes News;5/1/2010, Issue 602, p4 

    The article focuses on the ability of cladribine treatment to significantly reduce the use of healthcare resources in patients with relapsing-remitting multiple sclerosis (MS), according to the Cladribine Tablets in Treating MS Orally (CLARITY) study presented at the 62nd Annual Meeting of the...

  • Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis. Learmonth, Yvonne C.; Motl, Robert W.; Sandroff, Brian M.; Pula, John H.; Cadavid, Diego // BMC Neurology;2013, Vol. 13 Issue 1, p1 

    Background: The Patient Determined Disease Steps (PDDS) is a promising patient-reported outcome (PRO) of disability in multiple sclerosis (MS). To date, there is limited evidence regarding the validity of PDDS scores, despite its sound conceptual development and broad inclusion in MS research....


Read the Article


Sign out of this library

Other Topics